In vitro and in vivo drug interaction study of two lead combinations, oxantel pamoate plus albendazole and albendazole plus mebendazole, for the treatment of soil-transmitted helminthiasis

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 10, 2016, Pages 6127-6133

  Cowan, Noemi ^a,b   Vargas, Mireille ^a,b   Keiser, Jennifer ^a,b  

^a SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALBENDAZOLE; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; MEBENDAZOLE; OXANTEL EMBONATE; ANTHELMINTIC AGENT; CYTOCHROME P450; DRUG COMBINATION; ISOENZYME; PYRANTEL EMBONATE; SOIL;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; HELMINTHIASIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IC50; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; RAT; ULTRAVIOLET SPECTROSCOPY; ANALOGS AND DERIVATIVES; ANIMAL; BLOOD; DRUG COMBINATION; DRUG EFFECTS; DRUG INTERACTION; GENE EXPRESSION; GENETICS; GROWTH, DEVELOPMENT AND AGING; METABOLISM; MICROBIAL SENSITIVITY TEST; MOUSE; ORAL DRUG ADMINISTRATION; PARASITOLOGY; SOIL; SPRAGUE DAWLEY RAT; TRANSMISSION; TRICHURIASIS; TRICHURIS;

ADMINISTRATION, ORAL; ALBENDAZOLE; ANIMALS; ANTHELMINTICS; AREA UNDER CURVE; CYTOCHROME P-450 ENZYME SYSTEM; DRUG COMBINATIONS; DRUG INTERACTIONS; GENE EXPRESSION; ISOENZYMES; MEBENDAZOLE; MICE; MICROBIAL SENSITIVITY TESTS; PYRANTEL PAMOATE; RATS; RATS, SPRAGUE-DAWLEY; SOIL; TRICHURIASIS; TRICHURIS;

EID: 84992417433     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01217-16     Document Type: Article

References (36)

1. Pullan RL, Smith JL, Jasrasaria R, Brooker SJ. 2014. Global numbers of infection and disease burden of soil transmitted helminth infections in 2010. Parasit Vectors 7:37. http://dx.doi.org/10.1186/1756-3305-7-37.
2. Knopp S, Mohammed KA, Speich B, Hattendorf J, Khamis IS, Khamis AN, Stothard JR, Rollinson D, Marti H, Utzinger J. 2010. Albendazole and mebendazole administered alone or in combination with ivermectin against Trichuris trichiura: a randomized controlled trial. Clin Infect Dis 51:1420-1428. http://dx.doi.org/10.1086/657310.
3. Namwanje H, Kabatereine NB, Olsen A. 2011. Efficacy of single and double doses of albendazole and mebendazole alone and in combination in the treatment of Trichuris trichiura in school-age children in Uganda. Trans R Soc Trop Med Hyg 105:586-590. http://dx.doi.org/10.1016/j.trstmh.2011.07.009.
4. World Health Organization. 2012. Accelerating work to overcome the global impact of neglected tropical diseases. A roadmap for implementation. World Health Organization, Geneva, Switzerland.
5. Beach MJ, Streit TG, Addiss DG, Prospere R, Roberts JM, Lammie PJ. 1999. Assessment of combined ivermectin and albendazole for treatment of intestinal helminth and Wuchereria bancrofti infections in Haitian schoolchildren. Am J Trop Med Hyg 60:479-486.
6. Belizario VY, Amarillo ME, de Leon WU, de los Reyes AE, Bugayong MG, Macatangay BJC. 2003. A comparison of the efficacy of single doses of albendazole, ivermectin, and diethylcarbamazine alone or in combinations against Ascaris and Trichuris spp. Bull World Health Organ 81:35-42.
7. Speich B, Ali SM, Ame SM, Bogoch II, Alles R, Huwyler J, Albonico M, Hattendorf J, Utzinger J, Keiser J. 2015. Efficacy and safety of albendazole plus ivermectin, albendazole plus mebendazole, albendazole plus oxantel pamoate, and mebendazole alone against Trichuris trichiura and concomitant soil-transmitted helminth infections: a four-arm, randomised controlled trial. Lancet Infect Dis 15:277-284. http://dx.doi.org/10.1016/S1473-3099(14)71050-3.
8. Awadzi K, Edwards G, Duke BOL, Opoku NO, Attah SK, Addy ET, Ardrey AE, Quartey BT. 2003. The co-administration of ivermectin and albendazole - safety, pharmacokinetics and efficacy against Onchocerca volvulus. Ann Trop Med Parasitol 97:165-178. http://dx.doi.org/10.1179/000349803235001697.
9. Amsden GW, Gregory TB, Michalak CA, Glue P, Knirsch CA. 2007. Pharmacokinetics of azithromycin and the combination of ivermectin and albendazole when administered alone and concurrently in healthy volunteers. Am J Trop Med Hyg 76:1153-1157.
10. Gibson GG, Skett P. 2001. Introduction to drug metabolism, 3rd ed. Cengage Learning, Boston, MA.
11. Wienkers LC, Heath TG. 2005. Predicting in vivo drug interactions from in vitro drug discovery data. Nat Rev Drug Discov 4:825-833. http://dx.doi.org/10.1038/nrd1851.
12. Tucker GT, Houston JB, Huang S-M. 2001. Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential - towards a consensus. Br J Clin Pharmacol 52:107-117. http://dx.doi.org/10.1046/j.0306-5251.2001.temp.1441.x.
13. Cohen LH, Remley MJ, Raunig D, Vaz ADN. 2003. In vitro drug interactions of cytochrome p450: an evaluation of fluorogenic to conventional substrates. Drug Metab Dispos 31:1005-1015. http://dx.doi.org/10.1124/dmd.31.8.1005.
14. Cayen MN. 2011. Early drug development: strategies and routes to first-in-Human trials. John Wiley & Sons, New York, NY.
15. Rawden HC, Kokwaro GO, Ward SA, Edwards G. 2000. Relative contribution of cytochromes P-450 and flavin-containing monoxygenases to the metabolism of albendazole by human liver microsomes. Br J Clin Pharmacol 49:313-322.
16. Dayan AD. 2003. Albendazole, mebendazole and praziquantel. Review of non-clinical toxicity and pharmacokinetics. Acta Trop 86:141-159.
17. Pawluk SA, Roels CA, Wilby KJ, Ensom MHH. 2015. A review of pharmacokinetic drug-drug interactions with the anthelmintic medications albendazole and mebendazole. Clin Pharmacokinet 54:371-383. http://dx.doi.org/10.1007/s40262-015-0243-9.
18. Nishimuta H, Nakagawa T, Nomura N, Yabuki M. 2013. Significance of reductive metabolism in human intestine and quantitative prediction of intestinal first-pass metabolism by cytosolic reductive enzymes. Drug Metab Dispos 41:1104-1111. http://dx.doi.org/10.1124/dmd.113.051177.
19. Pfizer. 1973. A study of absorption of CP-14,445, a new pamoate, in man. Pfizer technical report. Pfizer, New York, NY.
20. Life Technologies. 2012. Vivid® CYP450 screening kits user guide. Life Technologies, Carlsbad, CA.
21. Trubetskoy OV, Gibson JR, Marks BD. 2005. Highly miniaturized formats for in vitro drug metabolism assays using vivid fluorescent substrates and recombinant human cytochrome P450 enzymes. J Biomol Screen 10:56-66. http://dx.doi.org/10.1177/1087057104269731.
22. Food and Drug Administration. 2001. Guidance for industry - bioanalytical method validation, May. Food and Drug Administration, Washington, DC.
23. Chou T-C. 2006. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58:621-681. http://dx.doi.org/10.1124/pr.58.3.10.
24. Zhang Y, Huo M, Zhou J, Xie S. 2010. PKSolver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel. Comput Methods Programs Biomed 99:306-314. http://dx.doi.org/10.1016/j.cmpb.2010.01.007.
25. Lodola A. 2011. Developing combination drugs in preclinical studies. Methods Mol Biol 691:3-16. http://dx.doi.org/10.1007/978-1-60761-849-2-1.
26. Olliaro P, Seiler J, Kuesel A, Horton J, Clark JN, Don R, Keiser J. 2011. Potential drug development candidates for human soil-transmitted helminthiases. PLoS Negl Trop Dis 5:e1138. http://dx.doi.org/10.1371/journal.pntd.0001138.
27. Bapiro TE, Egnell AC, Hasler JA, Masimirembwa CM. 2001. Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. Drug Metab Dispos 29:30-35.
28. Baliharová V, Velík J, Fimanová K, Lamka J, Szotáková B, Savlík M, Skálová L. 2005. Inhibitory effect of albendazole and its metabolites on cytochromes P450 activities in rat and mouflon in vitro. Pharmacol Rep 57:97-106.
29. Gottschall DW, Theodorides VJ, Wang R. 1990. The metabolism of benzimidazole anthelmintics. Parasitol Today 6:115-124. http://dx.doi.org/10.1016/0169-4758(90)90228-V.
30. Bekhti A, Pirotte J, Woestenborghs R. 1986. A correlation between serum mebendazole concentrations and the aminopyrine breath test. Implications in the treatment of hydatid disease. Br J Clin Pharmacol 21:223-226.
31. Merino G, Molina AJ, García JL, Pulido MM, Prieto JG, Alvarez AI. 2003. Intestinal elimination of albendazole sulfoxide: pharmacokinetic effects of inhibitors. Int J Pharm 263:123-132. http://dx.doi.org/10.1016/S0378-5173(03)00369-7.
32. Merino G, Jonker JW, Wagenaar E, Pulido MM, Molina AJ, Alvarez AI, Schinkel AH. 2005. Transport of anthelmintic benzimidazole drugs by breast cancer resistance protein (BCRP/ABCG2). Drug Metab Dispos 33:614-618. http://dx.doi.org/10.1124/dmd.104.003319.
33. Lespine A, Ménez C, Bourguinat C, Prichard RK. 2012. P-glycoproteins and other multidrug resistance transporters in the pharmacology of anthelmintics: prospects for reversing transport-dependent anthelmintic resistance. Int J Parasitol Drugs Drug Resist 2:58-75. http://dx.doi.org/10.1016/j.ijpddr.2011.10.001.
34. Lee HB, Blaufox MD. 1985. Blood volume in the rat. J Nucl Med 26:72-76.
35. Sakuda S, Akabane T, Teramura T. 2006. Marked species differences in the bioavailability of midazolam in cynomolgus monkeys and humans. Xenobiotica 36:331-340. http://dx.doi.org/10.1080/00498250600571749.
36. Keiser J, Utzinger J. 2008. Efficacy of current drugs against soil-transmitted helminth infections: systematic review and meta-analysis. JAMA 299:1937-1948. http://dx.doi.org/10.1001/jama.299.16.1937.